Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone Tablets, 40 mg/12.5 mg and 40 mg/25 mg (USRLD: Edarbyclor tablets).
Zydus Pharms Usa Inc Generic Azilsartan Medoxomil;Chlorthalidone Receives Tentative Approval in US
Alkem`s Generic Azilsartan Medoxomil, Chlorthalidone Receives Approval in the U.S.
Alembic's Generic Chlorthalidone Receives Approval in the U.S.
Mankind Pharma`s Generic Chlorthalidone Receives Approval in the U.S.
FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
FDA Confirms Paragraph IV Patent Litigation for Azilsartan Medoxomil and Chlorthalidomide
Tagi's Generic Chlorthalidone Receives Approval in the U.S.
Enforcement Report - Week of February 23, 2022
Inventia's Generic Chlorthalidone Receives Approval in the U.S.